H.C. Wainwright initiated coverage of Summit Therapeutics with a Buy rating and $16 price target. Summit is a clinical stage biotech company targeting treatment of various cancers, the analyst tells investors in a research note. The firm believes the shares are trading well below intrinsic valuation if ivonescimab continues to prove superior to Keytruda.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics files to sell 22.22M shares of common stock for holders
- Summit Therapeutics reports Q2 EPS (5c), consensus (6c)
- Summit Therapeutics Announces Q2 2024 Earnings Call Details
- Summit Therapeutics PLC (SMMT) Q2 Earnings Cheat Sheet
- Citi opens ‘positive catalyst watch’ on Summit Therapeutics